<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03826940</url>
  </required_header>
  <id_info>
    <org_study_id>CRU2C-ICNAS-001</org_study_id>
    <secondary_id>FLAD Life Science 2020</secondary_id>
    <nct_id>NCT03826940</nct_id>
  </id_info>
  <brief_title>From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1</brief_title>
  <acronym>ASD/NF1inhib</acronym>
  <official_title>Linking Inhibition From Molecular to Systems and Cognitive Levels: a Preclinical and Clinical Approach in Autism Spectrum Disorders and Neurofibromatosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Coimbra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Coimbra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate synaptic physiology and behavioral inhibition in patients with
      NF1 and ASD and to answer whether inhibitory deficits at these levels are modulated by
      lovastatin.

      Structure: (1) Visit 1: Baseline assessment- participant's characterization, baseline outcome
      measures and additional evaluations, (2) 3 consecutive days of physiologically probing
      drug/placebo intake, (3) Visit 2: Outcome measures and additional evaluations in the day
      after the last drug/placebo intake, (4) Washout period of 4 to 6 weeks, (5) 3 consecutive
      days of drug/placebo intake, (6) Visit 3: Outcome measures and additional evaluations in the
      day after the last placebo/drug intake.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The literature has shown synaptic inhibitory dysfunction in both ASD and NF1. Here the
      investigators aim to test whether a mechanistic link can be established between that synaptic
      inhibitory dysfunction, systems levels changes in oscillatory synchrony and regulation of
      inhibition and treatment with Lovastatin in these two neurodevelopmental disorders. The
      investigators will explore this link through the application of complementary quantitative
      measures (putative biomarkers), such as magnetic resonance spectroscopy (MRS) transcranial
      magnetic stimulation (TMS) and electroencephalogram (EEG) applied to the same group of adult
      patients before and after the lovastatin or placebo intake during three days.

      The intervention comprehends three sessions: the first two visits will occur in the same week
      and the third visit will take place 4 to 6 weeks later. In the first visit (baseline
      assessment), participants will perform neuropsychological, EEG, MRS and TMS assessment. In
      the other two visits participants will repeat EEG, MRS and TMS assessments to study possible
      post- intervention effects. Participants will intake 60mg of Lovastatin or Placebo during
      three consecutive days before the second and the third visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2019</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurochemical response changes to GABAergic stimulation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Comparing changes in brain excitation-inhibition measures (i.e., glutamate and GABA) when the GABAergic system is activated by oral dose of the Lovastatin 60mg during 3 days versus the placebo condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Motor evoked potentials changes under motor cortical stimulation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Amplitudes (mV) will be measured during stimulation of the primary motor cortex using transcranial magnetic stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortical excitability changes under motor cortical stimulation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Periods (ms) will be measured during stimulation of the primary motor cortex using transcranial magnetic stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain oscillations changes under sensory stimulation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Power (microV^2) will be recorded during sensory stimulation using high density electroencephalography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-related potentials changes under sensory stimulation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Amplitude (microV) will be recorded during sensory stimulation using high density electroencephalography.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <condition>Neurofibromatosis 1</condition>
  <arm_group>
    <arm_group_label>NF1 - experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NF1 - control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ASD - experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ASD - control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovastatin 60 MG</intervention_name>
    <description>60 MG Lovastatin per day for 3 consecutive days</description>
    <arm_group_label>ASD - experimental</arm_group_label>
    <arm_group_label>NF1 - experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>60 MG Placebo per day for 3 consecutive days</description>
    <arm_group_label>ASD - control</arm_group_label>
    <arm_group_label>NF1 - control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive diagnostic results for ASD in:

        The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.

          -  Positive diagnostic results for NF1:

        Clinical diagnosis based on the well-established clinical criteria

        Exclusion Criteria:

          -  Global Intelligence Quotient &lt; 80

          -  Associated medical condition such as epilepsy, neurologic conditions, genetic
             syndromes, or other usual comorbidity in ASD and NF1 populations

          -  Medication capable of interfering with the intervention and/or study results

          -  Pregnancy

          -  Drug use and/or alcohol abuse

          -  Contra-indications to MR and TMS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel S Castelo-Branco, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICNAS - Institute of Nuclear Sciences Applied to Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miguel S Castelo-Branco, MD, PhD</last_name>
    <phone>+351 239488510</phone>
    <phone_ext>518505</phone_ext>
    <email>mcbranco@fmed.uc.pt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sónia Pires</last_name>
    <phone>+351 239488510</phone>
    <phone_ext>518517</phone_ext>
    <email>soniapires@uc.pt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICNAS</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-043</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Castelo-Branco, MD PhD</last_name>
      <email>mcbranco@fmed.uc.pt</email>
    </contact>
    <contact_backup>
      <last_name>Inês Bernardino, PhD</last_name>
      <email>ines.s.bernardino@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <reference>
    <citation>Pizzarelli R, Cherubini E. Alterations of GABAergic signaling in autism spectrum disorders. Neural Plast. 2011;2011:297153. doi: 10.1155/2011/297153. Epub 2011 Jun 23. Review.</citation>
    <PMID>21766041</PMID>
  </reference>
  <reference>
    <citation>Violante IR, Ribeiro MJ, Edden RA, Guimarães P, Bernardino I, Rebola J, Cunha G, Silva E, Castelo-Branco M. GABA deficit in the visual cortex of patients with neurofibromatosis type 1: genotype-phenotype correlations and functional impact. Brain. 2013 Mar;136(Pt 3):918-25. doi: 10.1093/brain/aws368. Epub 2013 Feb 11.</citation>
    <PMID>23404336</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 23, 2019</study_first_submitted>
  <study_first_submitted_qc>January 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2019</study_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Coimbra</investigator_affiliation>
    <investigator_full_name>Miguel Castelo-Branco</investigator_full_name>
    <investigator_title>Research Director of CIBIT-ICNAS</investigator_title>
  </responsible_party>
  <keyword>Inhibition</keyword>
  <keyword>GABA</keyword>
  <keyword>molecular imaging</keyword>
  <keyword>functional magnetic resonance imaging</keyword>
  <keyword>Autism Spectrum Disorder</keyword>
  <keyword>Neurofibromatosis 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lovastatin</mesh_term>
    <mesh_term>L 647318</mesh_term>
    <mesh_term>Dihydromevinolin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

